focus
Previous article:
Heart attack and stroke risk calculators need revising
Next article: Sudafed saga points to U.S. issues with evaluating older drugs
Next article: Sudafed saga points to U.S. issues with evaluating older drugs
hotspot
hotspot
-
How the Dana
2025-10-01 07:24 -
How one patient went off dialysis — and others can too
2025-10-01 07:11 -
UpToDate has a racism problem: Dr. Stanley Goldfarb
2025-10-01 06:30 -
Security flaws in third
2025-10-01 05:55 -
Menendez indictment could see pharma lose a key ally
2025-10-01 05:46 -
After a drawn out lobbying fight, ARPA
2025-10-01 05:15